Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1981 1
1982 1
1991 1
1993 1
1994 1
1995 1
1998 3
1999 2
2004 3
2005 1
2006 2
2007 1
2009 1
2010 1
2012 1
2014 1
2015 3
2016 4
2020 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Kaufman PA, et al. Among authors: yelle l. J Clin Oncol. 2015 Feb 20;33(6):594-601. doi: 10.1200/JCO.2013.52.4892. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605862 Free PMC article. Clinical Trial.
Ultimate journey of the terminally ill: Ways and pathways of hope.
Daneault S, Lussier V, Mongeau S, Yelle L, Côté A, Sicotte C, Paillé P, Dion D, Coulombe M. Daneault S, et al. Among authors: yelle l. Can Fam Physician. 2016 Aug;62(8):648-56. Can Fam Physician. 2016. PMID: 27521394 Free PMC article.
Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, McCutcheon S, Kaufman PA, Forsythe A, Velikova G. Cortes J, et al. Among authors: yelle l. Breast Cancer Res Treat. 2015 Dec;154(3):509-20. doi: 10.1007/s10549-015-3633-7. Epub 2015 Nov 14. Breast Cancer Res Treat. 2015. PMID: 26567010 Free PMC article. Clinical Trial.
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J; 303 Study Group. Chan S, et al. Among authors: yelle l. J Clin Oncol. 1999 Aug;17(8):2341-54. doi: 10.1200/JCO.1999.17.8.2341. J Clin Oncol. 1999. PMID: 10561296 Clinical Trial.
Hope and noncurative chemotherapies: which affects the other?
Daneault S, Dion D, Sicotte C, Yelle L, Mongeau S, Lussier V, Coulombe M, Paillé P. Daneault S, et al. Among authors: yelle l. J Clin Oncol. 2010 May 1;28(13):2310-3. doi: 10.1200/JCO.2009.26.8425. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194838 No abstract available.
33 results